Literature DB >> 10344720

Microsatellite instability and loss of heterozygosity in prostatic carcinomas: comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases.

H Rohrbach1, C J Haas, G B Baretton, A Hirschmann, J Diebold, R P Behrendt, U Löhrs.   

Abstract

BACKGROUND: The molecular mechanisms leading to prostate cancer progression are poorly understood. In particular, those changes which are responsible for androgen-independent growth and metastatic spread in prostate cancer are an issue of current investigations.
METHODS: To gain more insight into these processes, paired microdissected samples from both untreated, locally advanced primary tumors (n = 20) and recurrences (n = 20) after conventional androgen-deprivation therapy (ADT) were analyzed retrospectively for microsatellite instability (MSI) and loss of heterozygosity (LOH) at nine loci on chromosomes 8, 18, and X by polymerase chain reaction. In parallel, 12 prostatic carcinomas treated by radical prostatectomy and nine corresponding lymph-node metastases were analyzed in the same way.
RESULTS: The group treated with ADT showed a total of 10 MSI in 7 of the primary tumors (35%): 4 of these (20%) at one locus, and 3 of these (15%) at two loci. In the recurrences, MSI was observed in 4 cases (20%): 3 of these at one locus (15%), and 1 of these (5%) at two loci. LOH was found in 8 cases (40%) before as well as after ADT. In the radically resected carcinomas, MSI could be detected at two chromosomal loci in one of the primary tumors (8%) and in one of the metastases (11%); LOH was found in 2 primaries (16%) and 3 metastases (33%).
CONCLUSIONS: Although MSI can be found in advanced prostatic carcinomas, it apparently does not play a major role in the progression of prostate cancer regarding androgen-independent growth or lymphogenous spread.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344720     DOI: 10.1002/(sici)1097-0045(19990615)40:1<20::aid-pros3>3.0.co;2-4

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

Review 1.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

2.  Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.

Authors:  Maximilian Burger; Stefan Denzinger; Christine G Hammerschmied; Andrea Tannapfel; Ellen C Obermann; Wolf F Wieland; Arndt Hartmann; Robert Stoehr
Journal:  J Mol Med (Berl)       Date:  2006-08-03       Impact factor: 4.599

Review 3.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

4.  Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Authors:  Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

5.  Genetic alterations and epigenetic alterations of cancer-associated fibroblasts.

Authors:  Heng Du; Guowei Che
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

Review 6.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2016-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.